stockrowXBiotech Inc.
XBIT Healthcare Biotechnology
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million.
- EPS
- −266.7%
- Free cash flow
- +25.3%
Quarter to June 2026, against a year earlier
Follow XBIT
Alert me
XBiotech Inc. (XBIT) EV/Sales
As of 6 November 2026, XBiotech Inc. (XBIT) trades at a EV/Sales of −10.5×. Over the past ten years it has ranged from −29.8× (April 2023) to 27.4× (April 2024); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −28.6× | — |
| FY2021 | 5.3× | (4.92%) |
| FY2020 | 5.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −28.6× | — |
| Sep 2022 | −13.4× | — |
| Jun 2022 | −4.9× | — |
| Mar 2022 | 2.2× | (58.08%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | −23.8× |
| XBIT XBiotech Inc. | −10.5× |
| BOLD Boundless Bio, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 0.2× |
| XLO Xilio Therapeutics, Inc. compare | 0.5× |
| GOSS Gossamer Bio, Inc. compare | 4.1× |
| CRDF Cardiff Oncology, Inc. compare | 39.8× |
| CLNN Clene Inc. compare | 196× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)